Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of phage medicines on tackling (a) recurrent and chronic urinary tract infections and (b) associated antimicrobial resistance.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises bacteriophage, or phage, medicines as a promising complementary option for difficult bacterial infections, including recurrent and chronic urinary tract infections (UTIs), and as a potential tool to address antimicrobial resistance (AMR).
However, phage therapy is not yet used routinely in the National Health Service. Although case reports and small studies show benefit in hard-to-treat infections, there is still insufficient largescale, high-quality clinical trial evidence to support widespread adoption.
For UTIs specifically, there is currently no evidence of benefit of phage therapy from randomised controlled trials, the only trial to date showed no effect. The proposed UK Clinical Phage Service will help generate further clinical evidence and support individual patient use where treatment options are limited.
As a result, phage therapy in the United Kingdom is generally accessed only through specialist or compassionate use pathways, typically when conventional antibiotics have failed and expert clinical teams judge it appropriate. This cautious approach ensures appropriate safety, efficacy, and regulatory oversight before routine use.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his department is taking to improve awareness and understanding of Type 1 Diabetes across the Health and Social Care system.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
As I reaffirmed in the Westminster Hall debate on type 1 diabetes on 9 March 2026, the Government is committed to improving awareness of type 1 diabetes. NHS England carried out communications activity to coincide with World Diabetes Day in November 2025, with a focus on the “4Ts” symptoms of type 1 diabetes, namely thirst, tired, thinning, and toileting, meaning increased urine output. This included messaging to the public via social media, and the cascade of information via clinical networks.
NHS England is currently engaging and coordinating with other national organisations on supportive action, raising awareness of the symptoms of type 1 diabetes, improving training and education, and exploring what supportive tools may be available to further support healthcare professionals to identify type 1 diabetes.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department is taking steps with the National Institute for Health and Care Excellence to introduce a definition for chronic urinary tract infections.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence‑based guidance for the National Health Service on best practice in the care and treatment of patients with specific conditions.
NICE does not ordinarily define specific clinical conditions. NICE has no current plans to develop guidance on chronic urinary tract infections (UTIs) at this time, and the topic has not been considered by its prioritisation board. However, NICE has produced a clinical guideline on antimicrobial prescribing for recurrent UTIs which provides recommendations on treatments and self-care for the prevention of recurrent UTIs. This guideline is available at the following link:
https://www.nice.org.uk/guidance/ng112
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his department is taking to help ensure the National Institute for Health and Care Excellence (NICE) recommended diabetes care guidelines are adhered to.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) guidelines provide recommendations on best practice in terms of both the effectiveness and cost-effectiveness of interventions and services. Guidelines describe best practice and National Health Service organisations are expected to take them fully into account in designing services that meet the needs of their local populations.
NICE guidance is not mandatory because it is designed as evidence-based advice to inform, rather than replace, clinical judgment, allowing for tailored care for individual patients. Guidelines cannot cover every unique patient scenario, and clinicians must maintain responsibility for treatment decisions.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support research on vaccinations against recurrent and chronic urinary tract infections.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR funds, supports, and carries out high-quality research to improve health outcomes and care services. Over the last five financial years, the Department has provided over £22 million in programme research funding for urinary tract infection (UTI) research, including research on improved treatment for recurrent and chronic UTIs. In addition, NIHR infrastructure is supporting Phase 3 trials on vaccines against Escherichia coli infection in older adults who have a history of UTI, delivered by the NIHR Bristol Clinical Research Facility and the NIHR Wellcome Trust Manchester Clinical Research Facility.
The NIHR also funds the James Lind Alliance, which has run a Priority Setting Partnership (PSP) focused on chronic and recurrent UTIs. This PSP, funded by AMR Action UK and delivered in partnership with Bladder Health UK and The Urology Foundation, has identified the top 10 research priorities in this area. A rolling funding opportunity is available for research projects that align with priorities aligning with PSPs.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of medical (a) gender inequality and (b) misogyny on the (i) diagnostics and (ii) treatment of urinary tract infections.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has not made a specific assessment. The National Institute for Clinical Excellence’s (NICE) guidelines, such as those for the diagnosis and management of urinary tract infections, are subject to equality impact assessments as part of NICE’s governance processes, which mean that protected characteristics, including sex, are considered as part of the guideline's development.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using uropathogen infection testing for diagnosing urinary tract infections.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has not made a specific assessment. There are several sources of guidance regarding the diagnosis of urinary tract infections (UTIs), including from the National Institute for Clinical Excellence and the UK Health Security Agency.
The TOUCAN study was part-commissioned by NHS England as an assessment of future more timely diagnostics, including various point of care tests for UTIs in primary care.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress has been made on incorporating menopause screening into NHS Health Checks.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We are currently working with experts, including general practitioners, to co-design the menopause content for the NHS Health Check.
The inclusion of menopause in the NHS Health Check will support eligible women across England to access high quality information on the menopause, including advice on managing symptoms and where to seek support.
We will ask local authorities to implement this addition in the NHS Health Checks later this year and will urge them to implement it as quickly as possible.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the introduction of HPV self-sampling planned for January 2026, a) what information and awareness-raising programmes are being developed to inform under-screened women of the advantages and disadvantages of the available cervical screening options and b) when will the programmes be rolled out.
Answered by Ashley Dalton
NHS England is committed to eliminating cervical cancer by 2040. Following ministerial endorsement of a UK National Screening Committee recommendation, in June 2025, NHS England indicated its intention to transform its approach to cervical screening for under-screened women. From early 2026, they will receive home testing kits starting with those that are the most overdue for screening. This will help tackle deeply entrenched barriers that keep some away from life-saving screening.
As part of implementation, NHS England is developing a communications and engagement plan to raise awareness of the option of self-testing. This includes underserved groups, NHS staff providing screening services, and key stakeholders such as charities. Materials developed have been tested with the Eve Appeal and build on extensive insights and user testing in the NHS cervical screening programme.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what factors are considered when allocating investment for research in the less survivable cancers; and what steps he is taking to combat underfunding for less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Cancer is one of the largest areas of spend at over £133 million in 2023/24, reflecting its high priority.
These investments are pivotal to informing our efforts to improve cancer prevention, treatment, and outcomes. An example of this investment is Imperial College London’s research on breath tests to detect less survivable cancers, including pancreatic cancer. Further information on the research is available at the following link:
https://imperialbrc.nihr.ac.uk/2023/06/05/imperial-led-uk-cancer-breath-tests-reach-final-stages/
Another example of Government investment was the launch of the NIHR’s national Brain Tumour Research Consortium in September 2024, which is bringing together researchers from a range of different disciplines and institutions with the aim of making scientific advances in how we prevent, detect, manage, and treat rare and less-survivable brain tumours in adults and children.
The NIHR welcomes further high-quality proposals from researchers to inform approaches to prevention, treatment, and care in relation to less survivable cancers. Furthermore, the Government is committed to ensuring that all patients have access to cutting-edge clinical trials and innovative, lifesaving treatments. The Government supports the Rare Cancers Bill and its ambitions to incentivise clinical trials and access to innovative treatments for rare cancers.
The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for less common cancers.